UK markets closed
NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,207.13 +444.10 (+2.50%) CRUDE OIL
79.17 +0.17 (+0.22%) GOLD FUTURES
2,316.30 +5.30 (+0.23%) DOW
38,267.47 +364.18 (+0.96%) Bitcoin GBP
47,355.49 +32.73 (+0.07%)
Cue Biopharma, Inc. (CUE)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
As of 02:57PM EDT. Market open.
| Previous close | 1.9050 |
| Open | 1.9100 |
| Bid | 1.8600 x 100 |
| Ask | 1.9000 x 400 |
| Day's range | 1.7601 - 1.9360 |
| 52-week range | 1.3030 - 5.1200 |
| Volume | |
| Avg. volume | 282,604 |
| Market cap | 91.449M |
| Beta (5Y monthly) | 2.01 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Here's Why Cue Biopharma (CUE) is Poised for a Turnaround After Losing -22.83% in 4 Weeks
Cue Biopharma (CUE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- Zacks
Here's Why Cue Biopharma (CUE) Is a Great 'Buy the Bottom' Stock Now
Cue Biopharma (CUE) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
- Thomson Reuters StreetEvents
Q4 2023 Cue Biopharma Inc Earnings Call
Q4 2023 Cue Biopharma Inc Earnings Call
© 2024 Yahoo. All rights reserved.